Autopsy report · NCT05079360

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Decided to halt and will potentially reopen in the future.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Veru Inc.
Sponsor type: Industry
Conditions: Metastatic Breast Cancer
Interventions: Sabizabulin; Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
Participants: 0
Sites: 26
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.